[go: up one dir, main page]

CA2353531A1 - Materiaux hydrogels produisant du monoxyde d'azote - Google Patents

Materiaux hydrogels produisant du monoxyde d'azote Download PDF

Info

Publication number
CA2353531A1
CA2353531A1 CA002353531A CA2353531A CA2353531A1 CA 2353531 A1 CA2353531 A1 CA 2353531A1 CA 002353531 A CA002353531 A CA 002353531A CA 2353531 A CA2353531 A CA 2353531A CA 2353531 A1 CA2353531 A1 CA 2353531A1
Authority
CA
Canada
Prior art keywords
macromer
regions
region
tissue
macromer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353531A
Other languages
English (en)
Inventor
Jennifer L. West
Kristyn Simcha Masters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2353531A1 publication Critical patent/CA2353531A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)

Abstract

L'invention concerne des hydrogels produisant du monoxyde d'azote (NO), de préférence photopolymérisables et biodégradables, pouvant libérer des quantités physiologiques de NO sur une durée prolongée, que l'on applique sur des sites ou à un patient nécessitant l'application de ce type de matériau pour le traitement de troubles comme la resténose, la thrombose, l'asthme, la cicatrisation, l'arthrite, la dysérection ou autres, dans lesquels le NO joue un rôle important. En règle générale, les hydrogels sont constitués de macromères, qui comprennent de préférence des zones biodégradables, et des groupes liés aux macromères sont libérés in situ, élevant ou modulant les niveaux de NO là où le traitement est requis. Les macromères peuvent former une homo ou hétéro-dispersion ou solution, polymérisée de manière à donner un matériau hydrogel qui, dans le dernier cas, peut être un réseau à semi-interpénétration ou à interpénétration. Les composés destinés à être libérés peuvent être physiquement emprisonnés, liés de façon covalente ou ionique au macromère, ou faire partie intégrante du matériau polymère. L'hydrogel peut être formé par réticulation ionique et/ou covalente. D'autres agents actifs (par exemple, thérapeutiques, prophylactiques ou diagnostiques) peuvent également être incorporés au matériau polymère.
CA002353531A 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote Abandoned CA2353531A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15205499P 1999-09-02 1999-09-02
US60/152,054 1999-09-02
PCT/US2000/024058 WO2001015738A2 (fr) 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote

Publications (1)

Publication Number Publication Date
CA2353531A1 true CA2353531A1 (fr) 2001-03-08

Family

ID=22541347

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353531A Abandoned CA2353531A1 (fr) 1999-09-02 2000-09-01 Materiaux hydrogels produisant du monoxyde d'azote

Country Status (7)

Country Link
EP (1) EP1194171A2 (fr)
AU (1) AU7101600A (fr)
CA (1) CA2353531A1 (fr)
CZ (1) CZ20011899A3 (fr)
IL (1) IL143305A0 (fr)
MX (1) MXPA01005338A (fr)
WO (1) WO2001015738A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052711B2 (en) 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US20020013261A1 (en) * 2000-05-18 2002-01-31 Robert Pawliuk Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers
JP4841066B2 (ja) * 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
EP1429829B1 (fr) 2001-09-05 2013-11-27 Geno LLC Generation d'oxyde nitrique
AU2003231157C1 (en) 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
EP1531868A2 (fr) * 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Agents therapeutiques contenant des nano-polymeres
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US7560076B2 (en) 2004-08-18 2009-07-14 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
CA2681308C (fr) 2007-03-23 2015-11-24 Geno Llc Conversion du dioxyde d'azote (no<sb>2</sb>) en oxyde nitrique (no)
WO2009097343A1 (fr) 2008-01-28 2009-08-06 Geno Llc Conversion de dioxyde d'azote (no2) en monoxyde d'azote (no)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
JP5878866B2 (ja) 2009-06-22 2016-03-08 ゲノ エルエルシー 一酸化窒素治療
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
JP5995724B2 (ja) 2009-11-20 2016-09-21 ゲノ エルエルシー 一酸化窒素送達システム
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (fr) 2011-02-28 2012-09-07 Novan, Inc. Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
HUP9801673A1 (hu) * 1998-07-24 2000-08-28 CYCLOLAB, Ciklodextrin Kutató-Fejlesztő Kft. Helyi vérbőséget fokozó gyógyszerkészítmények előállítása és alkalmazása

Also Published As

Publication number Publication date
WO2001015738A3 (fr) 2002-01-31
IL143305A0 (en) 2002-04-21
EP1194171A2 (fr) 2002-04-10
WO2001015738A2 (fr) 2001-03-08
CZ20011899A3 (cs) 2001-11-14
AU7101600A (en) 2001-03-26
MXPA01005338A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
US7279176B1 (en) Nitric oxide-producing hydrogel materials
JP4841066B2 (ja) 酸化窒素生成ヒドロゲル物質
US7052711B2 (en) Nitric oxide-producing hydrogel materials
KR100266912B1 (ko) 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
CA2353531A1 (fr) Materiaux hydrogels produisant du monoxyde d&#39;azote
US5626863A (en) Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
Sawhney et al. Bioerodible hydrogels based on photopolymerized poly (ethylene glycol)-co-poly (. alpha.-hydroxy acid) diacrylate macromers
Bohl et al. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation
US7022343B2 (en) Controlled release of anti-arrhythmic agents
US20030087985A1 (en) Gels for encapsulation of biological materials
US20020192182A1 (en) Polysaccharide-based polymerizable hydrogels
US20040138329A1 (en) Gels for encapsulation of biological materials
AU711031B2 (en) Covalent modification of surfaces with polymers to increase biocompatibility
WO1997032617A9 (fr) Modification covalente de surfaces au moyen de polymeres pour un accroissement de la biocompatibilite
EP1586349A1 (fr) Libération contr lée d&#39;agents anti-arrhythmiques
Shaker et al. Photocrosslinked Polymers: New Emerging Biomaterials for Controlled Drug Delivery and Other Biomedical Applications

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued